Abstract
In response to tissue trauma, viral invasion, or an insult of any etiology, the liver develops a localized inflammatory response, which serves to destroy, dilute, or wall off the injurious agent and the injured tissue. Under some circumstances, however, an excessive inflammatory response causes extensive liver damage and triggers acute liver failure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ramadori G, Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol 2001;13:777–84.
Bown MJ, Nicholson ML, Bell PR, et al. Cytokines and inflammatory pathways in the pathogenesis of multiple organ failure following abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2001;22:485–95.
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487–501.
Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009;36:4–12.
Streetz K, Leifeld L, Grundmann D, et al. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000;119:446–60.
Muto Y, Nouri-Aria KT, Meager A, et al. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988;2:72–4.
Tilg H, Vogel W, Aulitzky WE, et al. Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation. Transplantation 1990;49:1074–80.
Lau JY, Sheron N, Nouri-Aria KT, et al. Increased tumor necrosis factor-alpha receptor number in chronic hepatitis B virus infection. Hepatology 1991;14:44–50.
McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349–51.
Jirillo E, Caccavo D, Magrone T, et al. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 2002;8:319–27.
Tilg H. Cytokines and liver diseases. Can J Gastroenterol 2001;15:661–8.
Jazrawi SF, Zaman A, Muhamad Z, et al. Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs. Liver Transpl 2003;9:377–82.
Ladero JM, Fernández-Arquero M, Tudela JI, et al. Single nucleotide polymorphisms and microsatellite alleles of tumor necrosis factor alpha and interleukin-10 genes and the risk of advanced chronic alcoholic liver disease. Liver 2002;22:245–51.
Tsuchiya N, Tokushige K, Yamaguchi N, et al. Influence of TNF gene polymorphism in patients with acute and fulminant hepatitis. J Gastroenterol 2004;39:859–66.
Simeonova PP, Gallucci RM, Hulderman T, et al. The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. Toxicol Appl Pharmacol 2001;177:112–120.
Van Molle W, Denecker G, Rodriguez I, et al. Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins. J Immunol 1999;163:5235–41.
Leist M, Gantner F, Jilg S, et al. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol 1995;154:1307–16.
Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn’s disease with infliximab. Gastroenterol Clin North Am 2004;33:387–406.
Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932–9.
Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419–25.
Sharma P, Kumar A, Sharma BC, et al. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol 2009;50:584–91.
Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sci 2005;50:163–6.
Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004;53:1363–5.
Streetz KL, Luedde T, Manns MP, et al. Interleukin 6 and liver regeneration. Gut 2000;47:309–12.
Streetz KL, Tacke F, Leifeld L, et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology 2003;38:218–29.
Zhang D, Sun M, Samols D, et al. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 1996;271:9503–9.
Ramadori G, Van Damme J, Rieder H, et al. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol 1988;18:1259–64.
Iñiguez M, Berasain C, Martinez-Ansó E, et al. Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning. J Exp Med 2006;203:2809–15.
Wu D, Cederbaum AI. Alcohol, oxidative stress, and free radical damage. Alcohol Res Health 2003;27:277–84.
Lieber CS. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Avd. Pharmacol 1997;38:601–28.
Yamamoto Y, Yamashita S, Fujisawa A, et al. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 1998;247:166–70.
Cabré M, Ferré N, Folch J, et al. Inhibition of hepatic cell nuclear DNA fragmentation by zinc in carbon tetrachloride-treated rats. J Hepatol 1999;31: 228–34.
Corrales F, Giménez A, Alvarez L, et al. S-adenosylmethionine treatment prevents carbon tetrachloride-induced S-adenosylmethionine synthetase inactivation and attenuates liver injury. Hepatology 1992;16:1022–7.
Balsinde J, Winstead MV, Dennis EA. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett 2002;531:2–6.
Romano M, Clària J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003;17:1986–95.
Dudzinski DM, Serhan CN. Pharmacology of eicosanoids. In: Golan DE, Tashjian AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, Rose HS, eds. Principles of pharmacology: The pathophysiologic basis of drug therapy. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004:627–46.
Montuschi P, Barnes PJ, Roberts LJ, II. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18:1791–800.
Smith WL, Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat 2002;68–9:115–28.
Clària J. Cyclooxygenase-2 biology. Curr Pharm Des 2003;9:2177–90.
Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002;68–9:165–75.
Jakobsson PJ, Thoren S, Morgenstern R, et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999;96:7220–5.
Breyer RM, Bagdassarian CK, Myers SA, et al. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661–90.
FitzGerald GA, Patrono CN. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433–42.
Clària J, Arroyo V. Prostaglandins and other cyclooxygenase-dependent arachidonic acid metabolites and the kidney in liver disease. Prostaglandins Other Lipid Mediat 2003;72:19–33.
Bosch-Marcé M, Clària J, Titos E, et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 1999;116:1167–75.
López-Parra M, Clària J, Planagumà A, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002;135:891–900.
Clària J, Kent JD, López-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005;41:579–87.
Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001;108:25–30.
Tolman KG. Eicosanoids and the liver. Prostaglandins Other Lipid Mediat 2000;61:163–74.
Sinclair SB, Greig PD, Blendis LM, et al. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. J Clin Invest 1989;84:1063–9.
Lim SP, Andrews FJ, O’Brien PE. Misoprostol protection against acetaminophen-induced hepatotoxicity in the rat. Dig Dis Sci 1994;39:1249–56.
Cattral MS, Altraif I, Greig PD, et al. Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease. Am J Med 1994;97: 369–73.
Sterling RK, Luketic VA, Sanyal AJ, et al. Treatment of fulminant hepatic failure with intravenous prostaglandin E1. Liver Transpl Surg 1998;4: 424–31.
Núñez O, Fernández-Martínez A, Majano PL, et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004;53:1665–72.
Mohammed NA, El Aleem SA, El Hafiz HA, et al. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J Clin Pathol 2004;57:350–54.
Cheng J, Imanishi H, Iijima H, et al. Expression of cyclooxygenase 2 and cytosolic phospholipase A(2) in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol Res 2002;23:185–95.
Waris G, Siddiqui A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol 2005;79:9725–34.
Planagumà A, Clària J, Miquel R, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J 2005;19:1120–2.
Nanji AA, Miao L, Thomas P, et al. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat. Gastroenterology 1997;112:943–51.
Yu J, Ip E, Dela Pena A, et al. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology 2006;43:826–36.
Han C, Li G, Lim K, DeFrances MC, et al. Transgenic expression of cyclooxygenase-2 in hepatocytes accelerates endotoxin-induced acute liver failure. J Immunol 2008;181:8027–35.
Paik YH, Kim JK, Lee JI, et al. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut 2009; DOI: 10.1136/gut.2008.157420.
Graupera M, García-Pagán JC, Abraldes JG, et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003;37:172–81.
Yokoyama Y, Xu H, Kresge N, et al. Role of thromboxane A2 in early BDL-induced portal hypertension. Am J Physiol Gastrointest Liver Physiol 2003;284:G453–60.
Graupera M, March S, Engel P, et al. Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol 2005;288:G763–70.
Gracia-Sancho J, Laviña B, Rodríguez-Vilarrupla A, García-Calderó H, Bosch J, García-Pagán JC. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. J Hepatol 2007;47:220–7.
Yokoyama Y, Kawai T, Kawai S, et al. Up-regulated thromboxane production in the rat liver with biliary obstruction does not contribute to promote hepatic injury. Shock 2008;29:688–91.
Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001; 21:185–210.
Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995;83: 803–12.
Cernuda-Morollon E, Pineda-Molina E, Canada FJ, et al. 15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 2001;276:35530–6.
Gilroy DW, Lawrence T, Perretti M, et al. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004;3:401–16.
Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-delta12, 14-prostaglandin J2. J Biol Chem 1999;274:17042–8.
Kawahito Y, Kondo M, Tsubouchi Y, et al. 15-deoxy-12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000;106:189–97.
Maddox JF, Domsalski AC, Roth RA, et al. 15-deoxy prostaglandin J2 enhances allyl alcohol-induced toxicity in rat hepatocytes. Toxicol Sci 2004;77:290–8.
Morrow JD, Awad JA, Boss HJ, et al. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992;89:10721–5.
Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal 2008;10:1405–34.
Comporti M, Arezzini B, Signorini C, et al. Oxidative stress, isoprostanes and hepatic fibrosis. Histol Histopathol 2009;24:893–900.
Moore K. Isoprostanes and the liver. Chem Phys Lipids 2004;128:125–33.
Meagher EA, Barry OP, Burke A, et al. Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest 1999;104:805–13.
Morrow JD, Awad JA, Kato T, et al. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J Clin Invest 1992;90:2502–7.
Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171–6.
Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871–5.
Werz O. 5-lipoxygenase: cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy 2002;1:23–44.
Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233–9.
Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005;293:2245–56.
Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197–206.
Kuwabara K, Kiyoshi J, Hirokuni J, et al. Effects of the second-generation leukotriene B(4) receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice. Eur J Pharmacol 2000;402:275–85.
Aiello RJ, Bourassa PA, Lindsey S, et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002;22:443–9.
Keppler D, Hubler M, Baumert T. Leukotrienes as mediators in diseases of the liver. Semin Liver Dis 1988;8:357–66.
Titos E, Clària J, Bataller R, et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 2000;119:794–805.
Uemura M, Lehmann WD, Schneider W, et al. Enhanced urinary excretion of cysteinyl leukotrienes in patients with acute alcohol intoxication. Gastroenterology 2000;118:1140–8.
Moore KP, Taylor GW, Maltby NH, et al. Increased production of cysteinyl leukotrienes in hepatorenal syndrome. J Hepatol 1990;11:263–71.
Uemura M, Buchholz U, Kojima H, et al. Cysteinyl leukotrienes in the urine of patients with liver diseases. Hepatology 1994;20:804–12.
Clària J, Titos E, Jiménez W, et al. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology 1998;115:147–56.
Tiegs G, Wendel A. Leukotriene-mediated liver injury. Biochem Pharmacol 1988;37:2569–73.
Kawada N, Ueda N, Mizoguchi Y, et al. Increased 5-lipoxygenase activity in massive hepatic cell necrosis in the rat correlates with neutrophil infiltration. Hepatology 1992;16:462–8.
Bailie MB, Dahm LJ, Peters-Golden M, et al. Leukotrienes and alpha-naphthylisothiocyanate-induced liver injury. Toxicology 1995;100:139–49.
Shimazawa T, Nagai H, Koda A, et al. The effects of thromboxane A2 inhibitors (OKY-046 and ONO-3708) and leukotriene inhibitors (AA-861 and LY-171883) on CCl4-induced chronic liver injury in mice. Prostaglandins Leukot Essent Fatty Acids 1990;40:67–71.
Graupera M, García-Pagán JC, Titos E, et al. 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology 2002;122:387–93.
El-Swefy S, Hassanen SI. Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats. Ann Hepatol 2009;8:41–9.
Cuciureanu M, Căruntu ID, Păduraru O, et al. The protective effect of montelukast sodium on carbon tetrachloride induced hepatopathy in rat. Prostaglandins Other Lipid Mediat 2009;88:82–8.
Muller D, Enderle GJ, Low O, et al. Bile ductular proliferation and altered leukotriene elimination in thioacetamide-induced fibrosis of rat liver. J Hepatol 1996;25:547–53.
Titos E, Clària J, Planagumà A, et al. Inhibition of 5-Lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells. Implications in liver fibrosis. FASEB J 2003;17:1745–7.
Titos E, Clària J, Planagumà A, et al. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. J Leukoc Biol 2005;78:871–8.
Horrillo R, Planagumà A, González-Périz A, et al. Comparative protection against liver inflammation and fibrosis by a selective COX-2 inhibitor and a nonredox-type 5-LO inhibitor. J Pharmacol Exp Ther 2007;323:778–86.
Farzaneh-Far R, Moore K. Cysteinyl-leukotrienes and the liver. Prostagladins Other Lipid Mediat 2003;72:35–50.
Matsui N, Fukuishi N, Fukuyama Y, et al. Protective effect of the 5-lipoxygenase inhibitor ardisiaquinone A on hepatic ischemia-reperfusion injury in rats. Planta Med 2005;71:717–20.
Daglar G, Daglar G, Karaca T, et al. Effect of montelukast and MK-886 on hepatic ischemia-reperfusion injury in rats. J Surg Res 2009;153:31–8.
Acknowledgements
Our research is supported by grants from the Ministerio de Ciencia e Innovación (SAF 09/08767). CIBERehd is funded by the Instituto de Salud Carlos III.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Clària, J., López-Parra, M., Titos, E., González-Périz, A. (2011). The Role of Inflammatory Mediators in Liver Failure. In: Ginès, P., Kamath, P., Arroyo, V. (eds) Chronic Liver Failure. Clinical Gastroenterology. Humana Press. https://doi.org/10.1007/978-1-60761-866-9_7
Download citation
DOI: https://doi.org/10.1007/978-1-60761-866-9_7
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-865-2
Online ISBN: 978-1-60761-866-9
eBook Packages: MedicineMedicine (R0)